title: Effects of treatment with GH alone or in combination with LHRH analog on bone mineral density in pubertal GH-deficient patients.
abstract: The aim of the present study was to assess the impact of treatment with GH with or without LHRH analog (LHRH-A) on bone mineralization of GH-deficient adolescents. We studied 17 pubertal, treatment-naive, GH-deficient patients (10 girls and 7 boys) in a prospective, randomized trial. Mean chronological age and mean bone age were 14.1 +/- 0.4 and 11.3 +/- 0.3 yr, respectively, at the beginning of the study. Treatment with GH + LHRH-A (n = 7) or GH alone (n = 10) started simultaneously. Nutropin was administered at a dose of 0.1 U/kg per day sc until patients reached near final height (NFH), defined as a bone age of 14 yr in girls and 16 yr in boys. Mean time of GH therapy in the patients treated with GH+LHRH-A was 4.8 +/- 0.5 yr and in the patients treated with GH alone 2.9 +/- 0.7 yr. Lupron was administered at a dose of 300 microg/kg every 28 d im for 3 yr. Bone mineral density (BMD) was assessed yearly by dual-energy x-ray absorptiometry at the lumbar spine (L2-L4) and femoral neck at the beginning of the study, after 3 yr of hormonal therapy, and at NFH. Statistical analysis was performed by t test and ANOVA. We observed a significant increase in lumbar and femoral bone mineral content, BMD, SD score, and bone mineral apparent density, compared with baseline in both groups of patients, regardless of whether they were treated with GH alone or in combination with LHRH-A. The patients treated with GH + LHRH-A had a significantly lower bone mineral content after 3 yr of therapy. This difference, however, did not persist after both groups of patients reached NFH. These results indicate that delaying puberty with LHRH-A in GH-deficient patients treated with GH diminishes transient bone mineralization but does not appear to have a permanent impact on BMD.
authors.affiliation: Institute of Maternal and Child Research, University of Chile, Santiago, Chile.
authors.forename: Verónica
authors.initials: V
authors.lastname: Mericq
authors.forename: Héctor
authors.initials: H
authors.lastname: Gajardo
authors.forename: Martha
authors.initials: M
authors.lastname: Eggers
authors.forename: Alejandra
authors.initials: A
authors.lastname: Avila
authors.forename: Fernando
authors.initials: F
authors.lastname: Cassorla
mesh_terms: D000293:Adolescent; D001827:Body Height; D015519:Bone Density / Q000187:drug effects*; D002113:Calcification, Physiologic / Q000187:drug effects; D004338:Drug Combinations; D005272:Femur Neck; D005300:Fertility Agents, Female / Q000494:pharmacology; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000172:deficiency* / Q000494:pharmacology; D006801:Humans; D016729:Leuprolide / Q000494:pharmacology; D008159:Lumbar Vertebrae; D008297:Male; D011446:Prospective Studies; D011627:Puberty; D013997:Time Factors
chemical_list: D004338:Drug Combinations; D005300:Fertility Agents, Female; D019382:Human Growth Hormone; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide